News

Brain metastases are difficult to treat, often leaving patients with cancer with limited options and less favourable outcomes. The EViDENCE BM trial, just lauched, is designed to validate a cutting-edge personalised approach that could change the future of care for patients with brain metastases.

We've been selected as one of the charities for De Warmste Week, and this year we’re joining the flame for people who suffer out of sight. With the funds raised, we’ll set up workshops to help people cope with the often hidden consequences of cancer.

Researchers have completed the PROSPER trial, a clinical study examining whether two commonly available medications—propranolol and etodolac—could improve outcomes when administered around the time of pancreatic cancer surgery.

The European Medicines Agency (EMA) has released findings from its Pilot Program on drug repurposing, marking a significant step toward establishing new regulatory pathways that could transform how existing medicines are developed for new therapeutic uses across Europe.

New research published in the journal Cancer Research provides evidence that adaptive therapy represents a promising strategy to address one of oncology's challenges: drug resistance. Anticancer Fund is supporting clinical trials that explore this treatment approach, which offers a different perspective on how to treat cancer.

The Anticancer Fund is now part of FORCE, a major European initiative supporting research on rare and hard-to-treat cancers. Alongside 13 non-profit partners from 11 countries, we’re working to bring better, evidence-based treatments to patients who urgently need them.